According to results of a multi-center, placebo-controlled phase IIb trial, patients treated with laquinimod, a new type of immumodulatory agent for relapsing-remitting MS, had a 40% reduction in lesions.

References and Resources
Comi G, Pulizzi A, Rovaris A, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085-2092.

Sponsored by The Doctor’s C